<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002275</url>
  </required_header>
  <id_info>
    <org_study_id>041B</org_study_id>
    <nct_id>NCT00002275</nct_id>
  </id_info>
  <brief_title>A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)</brief_title>
  <official_title>Lipid-Based Parenteral Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome and Pneumocystis Carinii Pneumonia. A Comparison of Two Lipid Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
      To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent&#xD;
      as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia&#xD;
      (PCP). To compare the effects of the two lipid emulsions on immunologic function in AIDS&#xD;
      patients. To compare the effect of the two lipid emulsions on HIV load in AIDS patients as&#xD;
      measured by reverse transcriptase (RT) in culture. To determine whether a decrease in HIV&#xD;
      infectivity is greater in patients given a parenteral feeding regimen containing Liposyn II&#xD;
      20 percent or Liposyn III 2 percent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fat Emulsion 2%</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fat Emulsion 20%</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  All drugs used for the standard treatment of Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
          -  Other drugs for treatment of other AIDS conditions if they have been started more than&#xD;
             3 months prior to study entry.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Diagnosis of AIDS.&#xD;
&#xD;
          -  Weight loss &gt; 10 percent of premorbid body weight.&#xD;
&#xD;
          -  First or second episode of acute Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Do Not Resuscitate (DNR) status.&#xD;
&#xD;
          -  Biliary stasis.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Do Not Resuscitate (DNR) status.&#xD;
&#xD;
          -  Biliary stasis.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 3 months of study entry:&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Antiviral new DT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>East Orange Veterans Administration Med Ctr</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Martin DF, Parks DJ, Mellow SD, Ferris FL, Walton RC, Remaley NA, Chew EY, Ashton P, Davis MD, Nussenblatt RB. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol. 1994 Dec;112(12):1531-9. doi: 10.1001/archopht.1994.01090240037023.</citation>
    <PMID>7993207</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>February 19, 2009</last_update_submitted>
  <last_update_submitted_qc>February 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2009</last_update_posted>
  <keyword>Weight Loss</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Parenteral Nutrition</keyword>
  <keyword>Liposyn</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

